Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-598: Pembrolizumab + Ipilimumab in NSCLC
NCT03302234Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2017
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Dec 2017; status: completed.
02
Drugs
ipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03302234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03302234.